title: Therapeutic effect of interleukin 12 on mouse haemangiosarcomas is not associated with an increased anti-tumour cytotoxic T-lymphocyte activity.
abstract: In syngeneic mice, the H5V polyoma middle-T oncogene-transformed endothelioma cell line induces Kaposi's sarcoma-like cavernous haemangiomas that regress transiently, probably because of an anti-tumour immune response, but eventually grow progressively and kill the host. To evaluate the generation of tumour-specific cytotoxic T lymphocytes (CTLs), spleen cells of tumour-bearing mice were restimulated with irradiated H5V cells in mixed leucocyte-tumour cell cultures. Tumour-specific CTLs were demonstrable only when low numbers of H5V stimulator cells were used (<1 H5V cell per 50 splenocytes). We found that H5V cells secrete immunosuppressive mediators because CTL generation was blocked when H5V cells culture supernatants were added to allogeneic mixed leucocyte cultures. As numerous tumour-derived immunosuppressive mediators may interfere with interleukin 12 (IL-12) production, we tested whether IL-12 treatment of the tumour-bearing mice would augment their immune response and thus suppress tumour growth. Indeed, IL-12 inhibited tumour growth and prevented mortality, but did not increase anti-H5V CTL generation either in vitro or in vivo. Moreover, the anti-tumour activity in IL-12-treated mice was abrogated by anti-interferon (IFN)-gamma monoclonal antibody (MAb) co-administration. These results strongly suggest that the anti-tumour effect of IL-12 is principally mediated by IFN-gamma release that in turn blocks H5V cell proliferation and induces the release of factors that suppress angiogenesis.
authors.affiliation: Department of Oncology and Surgical Sciences, University of Padua, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Vizler
authors.forename: A
authors.initials: A
authors.lastname: Rosato
authors.forename: F
authors.initials: F
authors.lastname: Calderazzo
authors.forename: L
authors.initials: L
authors.lastname: Quintieri
authors.forename: P
authors.initials: P
authors.lastname: Fruscella
authors.forename: R
authors.initials: R
authors.lastname: Wainstok de Calmanovici
authors.forename: A
authors.initials: A
authors.lastname: Mantovani
authors.forename: A
authors.initials: A
authors.lastname: Vecchi
authors.forename: P
authors.initials: P
authors.lastname: Zanovello
authors.forename: D
authors.initials: D
authors.lastname: Collavo
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D006394:Hemangiosarcoma / Q000276:immunology* / Q000401:mortality / Q000628:therapy*; D007111:Immunity, Cellular; D007371:Interferon-gamma / Q000037:antagonists & inhibitors / Q000378:metabolism; D018664:Interleukin-12 / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D012878:Skin Neoplasms / Q000276:immunology* / Q000401:mortality / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D018664:Interleukin-12; D007371:Interferon-gamma